Long-Term Benefits and Limitations of Combined Antianginal Drug Therapy in Elderly Patients with Symptomatic Chronic Coronary Artery Disease

Background: Chronic angina is a common and disabling disorder in the elderly. Combined antianginal drug treatment represents the mainstay of therapy in this population. However, there is a paucity of data regarding the effect of this strategy on long-term outcome in the elderly. Methods: To assess the long-term effect of combined antianginal drug therapy in elderly individuals, we performed a long-term follow-up analysis of all 148 patients of the Trial of Invasive versus Medical therapy in Elderly (TIME) patients with chronic symptomatic coronary-artery disease assigned to an optimized medical therapy strategy. Angina severity, measures of quality of life (QOL), and survival were assessed after a median of 3.7 (0.1-6.9) years. Results: At baseline, patients were 79.8 ± 3.5 years old with Canadian Cardiovascular Society (CCS) class angina 3.0 ± 0.7 despite the use of 2.4 ± 0.6 antianginal drugs. Although antianginal drugs were increased to 2.8 ± 0.9 (P < .01), 63 (43%) patients needed revascularization for refractory symptoms during the first year of observation (REVASC). At baseline, REVASC patients had more frequently CCS class 4 angina (37% vs 20%, P < 0.05) but reported less prior heart failure (5% vs 20%, P < 0.01), fewer prior cerebral events (3% vs 13%, P < .05) and a lower rate of two or more comorbidities (10% vs 33%, P < .01) than patients on continued drug therapy (DRUG). At long-term follow-up, angina severity was still higher in DRUG compared to REVASC patients (CCS class, 1.8 ± 1.6 vs 1.0 ± 1.4, P < .05) despite more antianginal drugs (2.1 ± 1.1 vs 1.5 ± 1.0, P < .01), whereas measures of QOL had improved similarly in both groups. In addition, long-term mortality was significantly higher in DRUG than in REVASC patients (38% vs 13%, P < .01). Conclusion: Combined antianginal drug therapy successfully relieved symptoms in most elderly patients with chronic angina but failed to do so in 43%. Patients who needed revascularization for refractory symptoms reported less angina, despite lower drug use during long-term follow-up and had a better long-term survival. Thus, the widely used strategy to increase antianginal drug therapy in elderly patients instead of evaluating them for revascularization should be reconsidered.

[1]  M. Pfisterer,et al.  Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). , 2004, European heart journal.

[2]  M. Pfisterer.  Long-Term Outcome in Elderly Patients With Chronic Angina Managed Invasively Versus by Optimized Medical Therapy: Four-Year Follow-Up of the Randomized Trial of Invasive Versus Medical Therapy in Elderly Patients (TIME) , 2004, Circulation.

[3]  M. Pfisterer,et al.  Risks and benefits of optimised medical and revascularisation therapy in elderly patients with angina--on-treatment analysis of the TIME trial. , 2004, European heart journal.

[4]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[5]  P. Routledge,et al.  Adverse drug reactions in elderly patients. , 2003, British journal of clinical pharmacology.

[6]  M. Pfisterer,et al.  Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. , 2003, JAMA.

[7]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[8]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[9]  W. Hillis,et al.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial , 2002, The Lancet.

[10]  The Time Investigators.  Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial , 2001, The Lancet.

[11]  K. Alexander,et al.  Representation of elderly persons and women in published randomized trials of acute coronary syndromes. , 2001, JAMA.

[12]  M. Pfisterer.  Trial of Invasive versus Medical Therapy in the Elderly (TIME) , 2001, Heart Drug.

[13]  R. Blumenthal,et al.  Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. , 2000, Journal of the American College of Cardiology.

[14]  K. Anstrom,et al.  Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. , 2000, Journal of the American College of Cardiology.

[15]  K. Anstrom,et al.  Outcomes of cardiac surgery in patients > or = 80 years: results from the National Cardiovascular Network. , 2000, Journal of the American College of Cardiology.

[16]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[17]  J. M. Bloom.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. , 1999, The New England journal of medicine.

[18]  R. Beyth,et al.  Epidemiology of Adverse Drug Reactions in the Elderly by Drug Class , 1999, Drugs & aging.

[19]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[20]  RITA-2 trial participants.  Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial , 1997, The Lancet.

[21]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[22]  C. Held,et al.  Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) , 1996, European heart journal.

[23]  M. Bullinger.  German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. , 1995, Social science & medicine.

[24]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[25]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[26]  R. Kronmal,et al.  Prevalence of cardiovascular diseases among older adults : the cardiovascular health study , 1993 .

[27]  P. Hartigan,et al.  A Comparison of Angioplasty With Medical Therapy in the Treatment of Single-Vessel Coronary Artery Disease , 1992 .

[28]  P. Hartigan,et al.  A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. , 1992, The New England journal of medicine.

[29]  M A Hlatky,et al.  A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). , 1989, The American journal of cardiology.

[30]  A. L'Abbate,et al.  Long-term survival in medically treated patients with ischemic heart disease and prognostic importance of clinical and electrocardiographic data (the Italian CNR Multicentre Prospective Study ODI) , 1989 .

[31]  H. Blackburn,et al.  Cardiovascular survey methods. , 1969, Monograph series. World Health Organization.

[32]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[33]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[34]  K. Fox,et al.  Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. , 1996, European heart journal.